Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Trial Title: Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

NCT ID: NCT06496789

Condition: Gastric Adenocarcinoma

Conditions: Official terms:
Adenocarcinoma

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Intervention model description: Drug：Serplulimab+Oxaliplatin+S-1

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Serplulimab+SOX
Description: Serplulimab+Oxaliplatin+S1
Arm group label: Neoadjuvant chemotherapy

Summary: evaluate efficacy and safety of neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Criteria for eligibility:
Criteria:
Inclusion Criteria: - histologically documented adenocarcinoma of Gastric or Gastroesophageal Junction. 2. clinically diagnosed stage T3-4aN+M0 according to ultrasound endoscopy or enhanced CT/MRI scan. 3. Male or female. Age ≥ 18 years and ≤75 years. 4. surgeons participating in this study consider the lesion a resectable one. 5. ECOG 0~1 6. Physical condition and adequate organ function to ensure the success of abdominal surgery. 7. Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 × 109/L and Hemoglobin ≥90g/L. 8. Adequate liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 × ULN . ALP ≤ 2.5 × upper limit of normal (ULN); ALB ≥30g/L. 9. Adequate renal function: Serum creatinine ≤ 1.5 x ULN, and creatinine clearance ≥ 60 ml/min. 10. Adequate coagulation function: INR/PT≤ 1.5 x ULN, aPTT≤ 1.5 x ULN. 11. No serious concomitant disease that will threaten the survival of patients to less than 5 years. 12. Written (signed) informed consent. 13. Good compliance with the study procedures, including lab and auxiliary examination and treatment. 14. Female patients should not be pregnant or breast feeding. 15. PD-L1 assessment Exclusion Criteria: - patients with distant metastasis or unresectable primary lesion. 2. patients with T1, T2 lesion according to CT/MRI or ultrasound endoscopy. 3. history of chemo, radiation, immune therapy or radical resection for the GC/GEJ. 4. patients with active autoimmune disease or history of refractory autoimmune disease. 5. patients with active malignant tumor in recent 2 years, except the tumor studied in this research or cured locally tumor like resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ. 6. uncontrollable pleural effusion, pericardial effusion, or ascites in 2 weeks before recruitment. 7. patients who have digestive tract bleeding in 2 weeks before recruitment or with high risk of bleeding. 8. perforation / fistula of GI tract in 6 months before recruitment. 9. patients with upper GI tract obstruction or functional abnormality or malabsorption syndrome, which can affect absorption of S-1. 10. losing over 20% body weight in 2 months before recruitment. 11. pulmonary disease history: interstitial pulmonary disease, non-infective pneumonitis, pulmonary fibrosis, acute pulmonary disease. 12. uncontrollable systemic diseases, including diabetes, hypertension, etc. 13. severe chronic or active infections in need of systemic antibacterial, antifungal, or antiviral treatment, including TB or HIV, etc. 14. patients with untreated chronic hepatitis B or HBV DNA over 500 IU/ml or positive HCV RNA. 15. patients with any cardiovascular risk factors below: 1. cardiac chest pain occurring in 28 days before recruitment, defined as moderate pain that limits daily activity. 2. pulmonary embolism with symptoms occurring in 28 days before recruitment. 3. acute myocardial infarction occurring in 6 months before recruitment. 4. any history of heart failure reaching grade 3/4 of NYHA in 6 months before recruitment. 5. ventricular arrhythmias of Grade 2 or grater in 6 months before recruitment, or accompanied by supraventricular tachyarrhythmias requiring medical treatment. 6. cerebrovascular accident within 6 months before recruitment. 16. patients with peripheral neuropathy NCI CTC AE grade 1, except those with only deep tendon reflex disappearing. 17. moderate or severe renal injury [creatinine clearance rate≤50 ml/min (according to Cockroft & Gault equation)], or Scr>1.5 x ULN. 18. dipyrimidine dehydrogenase (DPD) deficiency. 19. allergic to any drug in this study. 20. history of allogeneic stem cell transplantation or organ transplantation. 21. use of steroids (dosage>10mg/d prednisone) or other systemic immune suppressive therapy in 14 days before recruitment, except patients treated with regimens below: a. steroids for hormone replacement (dosage>10mg/d prednisone); b. steroids for local application with little systemic absorption; c. short -term (≤ 7 days) steroids for preventing allergy or vomiting. 22. vaccinated with live vaccine in 4 weeks before recruitment. 23. receiving immune (interleukin, interferon, thymin) treatment or treatment of other trials in 28 days before recruitment. 24. receiving palliative radiation in 14 days before recruitment. 25. history of anti PD-1, PD-L1, PD-L2 or any other specific T cell costimulation or checkpoint pathway targeted treatment. 26. receiving operation in 28 days before recruitment, only if the operation is a minimally invasive one e.g. PICC. 27. for patients with uncontrolled epilepsy, CNS diseases or history of mental disorder, researchers should evaluate whether their diseases will impede their signing of informed consent or compliance of treatment.

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Locations:

Facility:
Name: Tianjin Medical University Cancer Institute & Hospital

Address:
City: Tianjin
Country: China

Status: Recruiting

Contact:
Last name: hongjie zhan, MD

Phone: 022-23109106
Email: hongjiezhan@163.com

Start date: May 27, 2023

Completion date: December 31, 2024

Lead sponsor:
Agency: Tianjin Medical University Cancer Institute and Hospital
Agency class: Other

Source: Tianjin Medical University Cancer Institute and Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06496789